Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054 · View on ClinicalTrials.gov ↗
Study Summary
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paltusotine
Study Locations (20)
Other
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo — Buenos Aires
- Sanatorio Guemes — Buenos Aires
- Centro de Endocrinologia y Diabetes Dr. A. Gutman ICM - Investigaciones — Buenos Aires
- Instituto Médico Especializado Alexander Fleming — Buenos Aires
Arizona
- Banner MD Anderson Cancer Center — Gilbert
California
- Hoag Memorial Hospital Presbyterian — Newport Beach
Connecticut
- Yale University - New Haven Hospital - Yale Cancer Center — New Haven
Florida
- Moffitt Cancer Center — Tampa
Georgia
- Winshop Cancer Institute - Emory University — Atlanta
Iowa
- University of Iowa Health Care — Iowa City
Kentucky
- University of Kentucky Medical Center — Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2030-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07087054
The ClinicalTrials.gov registry entry for NCT07087054 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crinetics Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 9 conditions, with Carcinoid Tumor appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07087054 reports 20 study locations spanning 17 distinct geographic areas — top geographies include Other, Arizona, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07087054 about?
NCT07087054 is a clinical study titled "Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen". A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to c...
What is the current status of trial NCT07087054?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2025-11-19. Estimated completion is 2030-01.
What conditions does trial NCT07087054 study?
This clinical trial studies the following conditions: Carcinoid Tumor, Carcinoid Syndrome, Carcinoid, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07087054?
The interventions under investigation include: Placebo (DRUG), Paltusotine (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07087054?
This trial is sponsored by Crinetics Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07087054 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.